Stoke Therapeutics STOK
NASDAQ STOK
$25.62 -0.39 (-1.50%)
At close: Oct 2, 2026 · 4:00 PM EDT

Stoke Therapeutics (STOK) Gains from Sales and Divestitures (2019 - 2025)

Updated

Stoke Therapeutics (STOK) recorded Gains from Sales and Divestitures of -$153,000 in Q4 2025.

Analysis

Stoke Therapeutics (STOK) Gains from Sales and Divestitures (2019 - 2025) Analysis & Trends

For FY2025, Stoke Therapeutics reported Gains from Sales and Divestitures of -$145,000.

  • Across earlier years, Gains from Sales and Divestitures came in at -$1,000 in FY2023 and -$29,000 in FY2021.
  • The Q4 2025 figure is the highest quarterly Gains from Sales and Divestitures since Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Stoke Therapeutics 1.60 Bn 429.41 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -153,000.00
Mar 31, 2021 -29,000.00
Mar 31, 2020 -3,000.00
Mar 31, 2019 -3,000.00
API Access

Stoke Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=STOK&period=max&api_key=YOUR_API_KEY